Daxas roflumilast: Additional Phase III data

Additional data from the double-blind, international Phase III HELIOS trial in 743 patients showed that once-daily 500 ug oral Daxas plus Spiriva tiotropium for 24 weeks significantly improved breathlessness as measured by a reduction

Read the full 341 word article

User Sign In